Outlook Therapeutics posts NORSE EIGHT phase 3 results for ONS-5010 in wet AMD

Outlook Therapeutics posted results this week from its completed phase 3 trial of ONS-5010 in wet AMD.

• NORSE EIGHT (NCT06190093) is a phase 3 trial that assessed the safety and effectiveness of intravitreally administered ONS-5010 compared to ranibizumab in subjects with neovascular age-related macular degeneration.¹ The study was completed, with a start date of January 24, 2024 and primary completion on November 7, 2024.¹ Enrollment reached 400 participants.¹ The primary outcome measured mean change in baseline best corrected visual acuity at week 8, using the Early Treatment Diabetic Retinopathy Study charts.¹ Posted results showed a mean change of 63.0 letters for ONS-5010 bevacizumab versus 66.2 letters for ranibizumab, with 9 of 200 ONS-5010 patients and 5 of 200 ranibizumab patients experiencing serious adverse events.¹